• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Peering Into Horizon Therapeutics's Recent Short Interest

    10/5/23 4:15:18 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HZNP alert in real time by email

    Horizon Therapeutics's (NYSE:HZNP) short percent of float has fallen 25.18% since its last report. The company recently reported that it has 7.10 million shares sold short, which is 3.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.38 days to cover their short positions on average.

    Why Short Interest Matters

    Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.

    Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.

    See Also: List of the most shorted stocks

    Horizon Therapeutics Short Interest Graph (3 Months)

    short_fig

    As you can see from the chart above the percentage of shares that are sold short for Horizon Therapeutics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.

    Comparing Horizon Therapeutics's Short Interest Against Its Peers

    Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.

    According to Benzinga Pro, Horizon Therapeutics's peer group average for short interest as a percentage of float is 3.74%, which means the company has less short interest than most of its peers.

    Did you know that increasing short interest can actually be bullish for a stock? This post by Benzinga Money explains how you can profit from it.

    This article was generated by Benzinga's automated content engine and was reviewed by an editor.

    Get the next $HZNP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HZNP

    DatePrice TargetRatingAnalyst
    11/1/2022$74.00Neutral
    H.C. Wainwright
    8/4/2022Outperform → Mkt Perform
    SVB Leerink
    6/14/2022$139.00Buy
    UBS
    6/6/2022$95.00Mkt Perform
    SVB Leerink
    5/23/2022$95.00Mkt Perform
    SVB Leerink
    3/15/2022$140.00Outperform
    Oppenheimer
    3/2/2022$135.00 → $140.00Overweight
    Morgan Stanley
    12/8/2021$137.00Overweight
    Wells Fargo
    More analyst ratings

    $HZNP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Watkins Thomas returned $20,550,600 worth of Ordinary Shares to the company (176,400 units at $116.50), closing all direct ownership in the company (SEC Form 4)

    4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)

    10/6/23 6:24:28 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mahony Susan returned $2,172,842 worth of Ordinary Shares to the company (18,651 units at $116.50), closing all direct ownership in the company (SEC Form 4)

    4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)

    10/6/23 6:22:58 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Witz Pascale returned $5,353,292 worth of Ordinary Shares to the company (45,951 units at $116.50), closing all direct ownership in the company (SEC Form 4)

    4 - Horizon Therapeutics Public Ltd Co (0001492426) (Issuer)

    10/6/23 6:21:24 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HZNP
    SEC Filings

    View All

    SEC Form 15-12G filed by Horizon Therapeutics Public Limited Company

    15-12G - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)

    10/16/23 4:44:27 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Horizon Therapeutics Public Limited Company

    S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)

    10/6/23 4:30:58 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Horizon Therapeutics Public Limited Company

    S-8 POS - Horizon Therapeutics Public Ltd Co (0001492426) (Filer)

    10/6/23 4:28:57 PM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HZNP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting

    Issues Letter to Fellow Shareholders Detailing Why Truly Independent Voices – Including a Shareholder Representative – Are Needed in the Dynavax Boardroom Highlights Concerns that Company's Misguided Acquisition Strategy Will Destroy Value and Prevent Dynavax from Maximizing the Benefit of Heplisav for Shareholders and Patients In Deep Track's View, Focusing on Heplisav Could Result in Nearly $2 Billion of Cash Being Returned to Shareholders by the End of 2030 Details Board's Poor Governance, Reactive Entrenchment Maneuvers, and Unwillingness to Work Constructively Believes Its Slate of Director Nominees Would Collectively Bring Valuable Shareholder Perspective and Independence as Well

    2/19/25 9:00:00 AM ET
    $AVTE
    $DVAX
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Rule 17(e) Announcement - Horizon Therapeutics plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the Scheme becoming effective Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that

    10/6/23 8:30:00 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rule 17(d) Announcement – Horizon Therapeutics plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement relating to the outcome of the Court Sanction Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces that the Irish H

    10/5/23 7:40:00 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HZNP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Horizon Pharma with a new price target

    H.C. Wainwright initiated coverage of Horizon Pharma with a rating of Neutral and set a new price target of $74.00

    11/1/22 7:30:31 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Horizon Pharma downgraded by SVB Leerink

    SVB Leerink downgraded Horizon Pharma from Outperform to Mkt Perform

    8/4/22 7:17:35 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Horizon Pharma with a new price target

    UBS initiated coverage of Horizon Pharma with a rating of Buy and set a new price target of $139.00

    6/14/22 7:20:43 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HZNP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Horizon Therapeutics Public Limited Company (Amendment)

    SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)

    2/9/23 11:22:19 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Horizon Therapeutics Public Limited Company (Amendment)

    SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)

    2/9/23 11:18:36 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Horizon Therapeutics Public Limited Company (Amendment)

    SC 13G/A - Horizon Therapeutics Public Ltd Co (0001492426) (Subject)

    2/7/23 10:33:00 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HZNP
    Leadership Updates

    Live Leadership Updates

    View All

    ACELYRIN Appoints Melanie Gloria as Chief Operating Officer

    LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D

    1/11/22 7:45:00 AM ET
    $ABBV
    $ABT
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HZNP
    Financials

    Live finance-specific insights

    View All

    Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 Announcement of Date of Court Hearing Horizon Therapeutics plc, a public limited company incorporated in Ireland ("Horizon" or the "Company") announces today that, in relation to the offer for the Company by Pillartre

    9/5/23 9:05:00 AM ET
    $HZNP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION

    THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly see

    9/1/23 9:20:00 AM ET
    $AMGN
    $HZNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

    Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's acquisition of Horizon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230831157622/en/ As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern D

    9/1/23 9:20:00 AM ET
    $AMGN
    $HZNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations